145 related articles for article (PubMed ID: 20131406)
1. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.
Teoh NC; Williams J; Hartley J; Yu J; McCuskey RS; Farrell GC
Hepatology; 2010 Mar; 51(3):996-1006. PubMed ID: 20131406
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
4. Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating eNOS and microparticle formation.
Ajamieh H; Farrell GC; McCuskey RS; Yu J; Chu E; Wong HJ; Lam W; Teoh NC
Liver Int; 2015 Sep; 35(9):2174-86. PubMed ID: 25786512
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease.
Hong F; Radaeva S; Pan HN; Tian Z; Veech R; Gao B
Hepatology; 2004 Oct; 40(4):933-41. PubMed ID: 15382116
[TBL] [Abstract][Full Text] [Related]
6. Hepatic ischemic preconditioning in mice is associated with activation of NF-kappaB, p38 kinase, and cell cycle entry.
Teoh N; Dela Pena A; Farrell G
Hepatology; 2002 Jul; 36(1):94-102. PubMed ID: 12085353
[TBL] [Abstract][Full Text] [Related]
7. Low-dose TNF-alpha protects against hepatic ischemia-reperfusion injury in mice: implications for preconditioning.
Teoh N; Leclercq I; Pena AD; Farrell G
Hepatology; 2003 Jan; 37(1):118-28. PubMed ID: 12500196
[TBL] [Abstract][Full Text] [Related]
8. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
9. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
[TBL] [Abstract][Full Text] [Related]
10. Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver.
Romics L; Kodys K; Dolganiuc A; Graham L; Velayudham A; Mandrekar P; Szabo G
Hepatology; 2004 Aug; 40(2):376-85. PubMed ID: 15368442
[TBL] [Abstract][Full Text] [Related]
11. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
Yu J; Ip E; Dela Peña A; Hou JY; Sesha J; Pera N; Hall P; Kirsch R; Leclercq I; Farrell GC
Hepatology; 2006 Apr; 43(4):826-36. PubMed ID: 16557554
[TBL] [Abstract][Full Text] [Related]
12. Endogenous danger signals trigger hepatic ischemia/reperfusion injury through toll-like receptor 4/nuclear factor-kappa B pathway.
Wang H; Li ZY; Wu HS; Wang Y; Jiang CF; Zheng QC; Zhang JX
Chin Med J (Engl); 2007 Mar; 120(6):509-14. PubMed ID: 17439747
[TBL] [Abstract][Full Text] [Related]
13. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury.
Yang YY; Lee PC; Huang YT; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Lee TY; Lin HC
Clin Sci (Lond); 2014 Jan; 126(2):163-74. PubMed ID: 23875703
[TBL] [Abstract][Full Text] [Related]
15. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Yang YY; Huang YT; Lee TY; Chan CC; Yeh YC; Lee KC; Lin HC
Liver Transpl; 2012 Nov; 18(11):1371-83. PubMed ID: 22847887
[TBL] [Abstract][Full Text] [Related]
16. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
17. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
[TBL] [Abstract][Full Text] [Related]
18. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
19. NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses.
Locatelli I; Sutti S; Vacchiano M; Bozzola C; Albano E
Clin Sci (Lond); 2013 Feb; 124(4):279-87. PubMed ID: 22970906
[TBL] [Abstract][Full Text] [Related]
20. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
